Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.86 EUR
Change Today -0.018 / -2.05%
Volume 0.0
As of 2:08 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VCC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - €1.05
52 Week Low
12/16/14 - €0.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VICAL INC (VCC)

vical inc (VCC) Related Bloomberg News

View More Bloomberg News

vical inc (VCC) Related Businessweek News

No Related Businessweek News Found

vical inc (VCC) Details

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 02/26/15
Founded in 1987

vical inc (VCC) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $821.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $292.2K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $344.8K
Vice President of Vaccine Research
Total Annual Compensation: $337.8K
Compensation as of Fiscal Year 2014.

vical inc (VCC) Key Developments

Vical Incorporated Mulls Acquisitions

Vical Incorporated (NasdaqGS:VICL) is seeking acquisitions. Vical Incorporated has filed a Shelf Registration in the amount of $100.00 million. Vical Incorporated said it will use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses, and potential acquisitions of companies and technologies that complement our business.

Vical Incorporated Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients

Vical Incorporated announced the completion of enrollment in a Phase 2 trial of its therapeutic cytomegalovirus (CMV) vaccine in solid organ transplant recipients. ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma Inc. Enrollment in the Phase 2 trial was completed almost a year ahead of schedule. A total of 150 kidney transplant recipients were enrolled, exceeding the original enrollment target of 140. The trial has enrolled subjects at approximately 80 centers in North America, Europe and Australia. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of ASP0113 in CMV-seronegative kidney transplant recipients receiving an organ from a CMV-seropositive donor (D+/R-). The primary endpoint will evaluate efficacy of ASP0113 with 100 days of valganciclovir – compared to placebo with 100 days of valganciclovir – in reducing the incidence of CMV viremia over a period of one year following the first vaccination. Secondary endpoints include incidence of CMV disease, overall survival, and others. Topline trial results are expected in the second half of 2016.

Vical Incorporated Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Vical Incorporated reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $4,944,000 compared to $2,447,000 for the same period of last year. Loss from operations was $3,857,000 compared to $3,483,000 for the same period of last year. Net income was $3,821,000 or $0.04 per basic and diluted share compared to $3,455,000 or $0.04 per basic and diluted share for the same period of last year. The increase in revenues is primarily the result of an increase in vaccine deliveries to be used in clinical trials and in process development work under contract with Astellas related to the ASP0113 vaccine program.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCC:GR €0.86 EUR -0.018

VCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $7.85 USD +0.0592
Dynavax Technologies Corp $21.89 USD -0.65
GenVec Inc $2.29 USD -0.03
Inovio Pharmaceuticals Inc $8.42 USD +0.08
Peregrine Pharmaceuticals Inc $1.41 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at